Summary: We compared 956 samples for AMPLICOR Neisseria gonorrhoeae polymerase chain reaction (PCR) (Roche) with species verification using the 16S rRNA gene to verification using gyrA gene. Control was the culture method. The gyrA verification uses pyrosequencing of the quinolone resistance-determining region of gyrA. Of 52 samples with optical densityX0.2 in PCR, 27 were negative in culture, two samples from pharynx were false negative in culture and four samples from pharynx were false positives in verification with 16S rRNA. Twenty-five samples showed growth of gonococci, 18 of the corresponding PCR samples were verified by both methods; three urine samples were positive only in gyrA; and one pharynx specimen was positive only in 16S rRNA. Three samples were lost. We conclude that AMPLICOR N. gonorrhoeae PCR with verification in gyrA gene can be considered as a diagnostic tool in populations with low prevalence of gonorrhoea and that pharynx specimens should not be analysed by PCR.
Introduction
Neisseria gonorrhoeae is strictly a human pathogen and not considered to be a part of the normal bacterial flora. The classical symptoms of gonorrhoea are massive urethral or vaginal discharges, but also asymptomatic infections will transmit the disease, and therefore also require treatment. Rectum and pharynx are more frequently involved in asymptomatic infections, which are found both in men and women.
1,2 Diagnosis of asymptomatic gonorrhoea, especially in low-prevalence settings, requires a laboratory method with high sensitivity.
Several commercial kits for molecular diagnosis of N. gonorrhoeae have been evaluated, and they do not require living bacteria and are easy to perform. [2] [3] [4] [5] [6] Urine samples can be used, which are the most common samples for detection of Chlamydia trachomatis. Certain commercial kits, such as Cobas AMPLICOR (Roche Diagnostics, Indianapolis, IN, USA), can detect N. gonorrhoeae and C. trachomatis in a duplex polymerase chain reaction (PCR). 2, 6, 7 There are also reports that molecular laboratory diagnosis of gonorrhoea has increased sensitivity compared with culture, especially in samples from rectum, pharynx and synovial fluids. 4, 5 However, Cobas AMPLICOR N. gonorrhoeae PCR is approved only for testing N. gonorrhoeae in samples from urine, urethra and cervix.
The major disadvantage of molecular diagnostics of N. gonorrhoeae is that susceptibility tests can only be performed on isolated strains. Another disadvantage is low specificity, and all commercial kits are known to give false-positive results. [2] [3] [4] 8 Therefore, molecular diagnostics requires a confirmatory PCR targeting another part of the genome, which will decrease the risk of falsepositive results. 2, 3 The AMPLICOR N. gonorrhoeae PCR targets the M-Ngo PII gene encoding cytosine DNA methyltransferase and Roche Diagnostics recommends a region in the multicopy gene for 16S rRNA for confirmation. 7 The quinolone resistance-determining region (QRDR) of gyrA has also been evaluated as a confirmatory region. 9 The Swedish National Guidelines for laboratory diagnosis of N. gonorrhoeae recommend culture, followed by confirmatory tests and sensitivity testing. 10 In N. gonorrhoeae, resistance to antimicrobial agents has emerged and susceptibility pattern varies between strains, dependent on treatment preferences in different parts of the world. 11 The aim of the study was to investigate how AMPLICOR N. gonorrhoeae PCR performs compared with culture in clinical samples, and to compare confirmation by PCR of 16S rRNA as recommended by Roche Diagnostics, to confirmation by sequencing of QRDR in gyrA.
Methods
Swabs (n ¼ 956), from urethra, cervix/urethra, rectum or pharynx, were sent to the Clinical Bacteriological Laboratory at Karolinska University Hospital Huddinge, Stockholm County, Sweden, for culture of N. gonorrhoeae. These swabs were accompanied by urine samples; cervix swabs in urine; swabs from rectum or pharynx, respectively, for AMPLICOR C. trachomatis PCR. The samples for C. trachomatis diagnostics were also analysed in AMPLICOR N. gonorrhoeae PCR by a duplex PCR. The samples were collected between February and November 2002 from 20 clinics in southern Stockholm. Twenty-four additional pharynx specimens for culture and PCR were collected from patients without symptoms or history of gonorrhoea. The study was approved by the regional ethic committee, and informed consent was obtained from the patients.
The AMPLICOR N. gonorrhoeae PCR was performed according to the manufacturer's instructions. 7 The AMPLICOR method is an automated PCR, used for designed kits. The results are shown as optical density (OD) from a photometer.
DNA from PCR-positive samples was extracted by QIAampt viral RNA mini kits (QIAGEN Inc., Valencia, CA, USA). The purified DNA samples were run in PCR with the primers for species verification of N. gonorrhoeae by 16S rRNA using protocol and primers SL67 and SL59 previously published by Farrell 2 (Table 1) . PCR for 16S rRNA was performed in a 50 mL master mix containing 5 mL of 10 Â PCR Gold Buffer (Applied Biosystems, Foster City, CA, USA), 3.0 mL 25 mM MgCl 2 , 1.0 mL of each of the two primers (20 pM), 1.0 mL of a 10 mM mix of deoxynucleoside triphosphates (Sigma Aldrich, Stockholm, Sweden), 0.25 mL of 5 U/mL AmpliTaq Goldt (Applied Biosystems, Stockholm, Sweden) and 28.75 mL sterile water, and 10 mL of the template DNA. The target regions were amplified by the PCR method using the following temperature profile: initial heating at 951C for 10 min, a cycle of denaturation at 941C for 1 min, annealing at 551C, elongation at 721C for 2 min, repeated in 30 cycles with a final elongation at 721C for 7 min, followed by gel electrophoresis.
The same material after DNA extraction was run in PCR with primers for gyrA, gyrA2-1 and gyrA2-2, previously published by Lindbäck et al.
9 (Table 1) , followed by gel electrophoresis and pyrosequencing using the primer gyrA2-3.
9
N. gonorrhoeae was identified as oxidase-positive, Gram-negative diplococci with typical sugar oxidation. 1 Production of b-lactamase was detected by nitrocefin disks. 12 MIC of ciprofloxacin was determined by Etestt (AB Biodisk, Solna, Sweden) 13 on chocolate agar base.
14 Serogroups WI and WII/III of the isolates were determined by a coagglutination test using Phadebact Monoclonal GC kit (Boule Diagnostics AB, Huddinge Sweden) according to the manufacturer's instructions. 15 Serovar of the isolates was also determined by a coagglutination method using a panel of 14 monoclonal antibodies to protein I (Ar, Ao, As, At, Av, Br, Bo, Bp, By, Bv, Bu, Bs, Bt and Bx; Boule Diagnostics AB) as described earlier in detail. 15 Serogroups WI and WII/III correspond to serovars A and B, respectively.
As controls for species verification by 16S rRNA primers, strains of N. gonorrhoeae (ATCC 43069), N. sicca (ATCC 9913), N. lactamica (ATCC 23970, CCUG 17628), N. subflava (CCUG 32186, CCUG 30607), N. flavescens (CCUG 17913, CCUG 806 and CCUG 26476), N. cinerea (CCUG 25879, CCUG 27178), N. mucosa (CCUG 26877), N. meningitidis (ATCC 13090, ATCC 13077), and two clinical strains of N. meningitidis (424, 223), Escherichia coli (ATCC 25922), and Lactobacillus acidophilus (ATCC 4356) were also run in PCR and AMPLICOR N. gonorrhoeae PCR (Roche Diagnostics). The sequences were analysed as previously described, 16 N. gonorrhoeae ATCC 700825, as well as results of a neisseria verification study, 9 was used as the basis of the evaluation.
Results and discussion
The results of serotyping, b-lactamase (data not shown) and MIC of ciprofloxacin in the 22 N. gonorrhoeae-positive cultures from 18 different patients indicated 11 different patterns (Table 2) .
Fifty-two of 956 samples for N. gonorrhoeae Cobas AMPLICOR (Roche Diagnostics) PCR gave OD over the background level of 0.2, and 39 of these had OD>1.5. None of the 13 samples with OD between 0.2 and 1.5 verified positive in either of the two verifications, and none of the correlating cultures were positive. Of the 39 samples with OD>1.5, 14 showed no growth, but two of these samples, both from pharynx, were positive in both verification methods. Eight samples were negative in both verifications and four were positive in 16S rRNA verification and negative in gyrA verification.
Of the 25 samples that showed growth and had OD >1.5 in PCR, 22 samples were analysed and three samples were lost. Eighteen samples were positive in both verifications, three were positive in gyrA and negative in 16S rRNA, and one was positive in 16S rRNA and negative in gyrA.
Two negative cultures, both from pharynx, were positive in correlating PCR samples and were verified by both methods. One of the patients had positive cultures from urethra and rectum taken on the same day. We regard these two cultures as falsenegative cultures. The false-negative results were probably due to overgrowth of the normal flora containing saprophytic Neisseria spp. in the human pharynx.
Verification by 16S rRNA produced seven incorrect diagnoses, three of these were false negatives all from urine, and four were false positives, all from pharynx. Two of the patients with falsenegative results from urine had correlating gonococcal isolates from urethra and one had an isolate from urethra/cervix, respectively. The four falsepositive samples in 16S rRNA were all negative both in culture and verification by the gyrA method.
Verification by gyrA method resulted in one false-negative sample from pharynx. Despite several reruns, the sequence in gyrA was identical to N. meningitidis/N. lactamica. 9 However, the gonococcal strain in the corresponding culture sample had a DNA sequence in gyrA, typical for N. gonorrhoeae. The erroneous result may have been due to the presence of relatively high numbers of other Neisseria spp. in the pharynx of that patient. Interestingly, the 16S rRNA primers produced a PCR product that gave a visible band in gel electrophoresis in seven different strains of other Neisseria spp. than N. gonorrhoeae, shown in Table 3 .
Pharynx samples from 24 patients without suspicion of gonorrhoea were all negative in cultivation, but 16 gave an OD >1.5, and two specimens gave also a positive 16S rRNA verification. All 24 samples were negative in verification by gyrA.
Susceptibility indication by gyrA performed well, since all 21 verifications with correlating strains were correctly diagnosed in the molecular ciprofloxacin susceptibility test, where 17 strains were susceptible and four strains showed reduced susceptibility determined by Etest (Table 2) . Even if resistance to ciprofloxacin in N. gonorrhoeae is emerging all over the world, 10,17 a ciprofloxacinsusceptible strain is still possible to eliminate with this drug, and therefore we think that the gyrA sequence as a susceptibility indicator for ciprofloxacin adds valuable information to the verification, even if a few ciprofloxacin-resistant N. gonorrhoeae strains without alterations in QRDR of gyrA have been reported. 18 Diemert et al. have evaluated the AMPLICOR N. gonorrhoeae PCR in a low-prevalence population of 0.5%. 8 Their study only included samples from urine, urethra and cervix. Of 737 samples for AMPLICOR N. gonorrhoeae PCR with corresponding cultures, 29 had ODX0.2. Seven cultures were positive and all of them were positive in AMPLICOR, as well as verification by 16S rRNA. In our material, we had four samples, all from pharynx, regarded as false positives. These observations and the two positive results from pharynx from 24 patients without any suspicion of gonorrhoea certainly affected the 16S rRNA verification method in terms of specificity, even if our study included different specimen types. We concluded that our material is too limited to present as statistical data of specificity and sensitivity, so we have chosen to present data as observations.
In a multicentre evaluation, Martin et al. 6 compared the AMPLICOR N. gonorrhoeae test to culture in 4173 matched samples; however, they only included endocervical and urethral swabs matched to urine samples. They regarded all samples with ODX3.5 as positives and verified samples without correlating growth with 0.2pOD o3.5 with the 16S rRNA method, which means that the study did not evaluate possible false negatives in the verification method. In our study, we had three samples from pharynx and one urine sample, all regarded as negatives with ODX3.5.
Farrell has evaluated the AMPLICOR N. gonorrhoeae PCR and verification by 16S rRNA as well as by the stncppB gene in several N. gonorrhoeae and Neisseria spp. strains. 2 He found no Neisseria spp. strain that produced a positive PCR result in either of the verification methods. However, we found that two strains of N. cinerea gave positive reaction in AMPLICOR and that 10 out of 15 strains representing various Neisseria spp. gave positive 16S rRNA verification (Table 3) .
We think that the most possible explanation for the false-positive AMPLICOR and 16S rRNA verification results in pharynx specimens is due to amplification of DNA from species other than N. gonorrhoeae. To support this, the four samples regarded as false positives in verification by 16S rRNA had gyrA sequences in verification identical or similar to other Neisseria spp. Two of the samples had sequences identical to N. meningitidis/ N. lactamica, one had a sequence identical to N. subflava/N. flavescens and one had an unknown sequence differing in two nucleotides from the N. subflava/N. flavescens sequence, differing in four nucleotides from the N. gonorrhoeae sequence. 9 Roche Diagnostics as well as Diemert et al. recommend verification by the 16S rRNA method for all samples with ODX0.2. 7, 8 In this study, the lowest OD value regarded as a positive was from pharynx, with OD ¼ 1.8. Correlating samples from this patient were positive in culture and verification by 16S rRNA. This sample was the only one that we could not verify by the gyrA method. We think that if this method is established, the OD breakpoint for verification may be elevated.
Even with these limited observations, we conclude that verification by 16S rRNA produced false-positive results. Verification by gyrA is probably a more specific method, which also includes a unique possibility to combine verification with a molecular ciprofloxacin susceptibility indicator. Culture and PCR combined with either verification method produce false-negative results, which probably are something laboratory testing will always face; however, methods that produce false positives have serious implications. Pharynx is by far the most troublesome sample collection site in this study, both for culture and PCR combined with either of the verification methods, probably due to a rich normal flora including several Neisseria spp. We think that molecular diagnostics of N. gonorrhoeae with the gyrA method as verification can be considered as a diagnostic tool in populations with a low prevalence for gonorrhoea. For example, when the clinician today chooses to test only for C. trachomatis, or when a patient with risk behaviour has no symptoms, but wishes to be tested, the molecular test could add valuable information. The molecular method with verification by gyrA is simple to perform; urine samples can be analysed; is fast, especially for negative results; has good sensitivity and sufficient specificity compared with culture. Since the gene for16S rRNA occurs in more than one copy per chromosome, verification using this gene should have a higher sensitivity. However, we have not been able to confirm this, and false-positive results may not only give a wrong diagnosis but can also cause legal problems. Patients who have symptoms that qualify for treatment before the result of the laboratory diagnosis should always be diagnosed by culture, and, if possible, patients with positive results from molecular diagnostics should be retested by culture, to obtain a susceptibility test to different antimicrobial agents. Since pharynx specimens give both false-negative and falsepositive results, such specimens should not be tested by PCR, at least not with the primers and verification methods used in this study.
